New York, NY -- (SBWIRE) -- 12/24/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX), Coronado Biosciences Inc (NASDAQ:CNDO), Cereplast Inc (OTCMKTS:CERP), Dendreon Corporation (NASDAQ:DNDN),
Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) showed a volume of 1.14 million shares by the end of last trade whereas the average volume of the stock remained 1.34 million shares. The stock opened the session at $1.81 but then moved to $1.91. At that price, the stock showed a positive performance of 6.11%. Lexicon Pharmaceuticals, Inc. (Lexicon Pharmaceuticals) is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon Pharmaceuticals uses its gene knockout technologies and an integrated platform of medical technologies to study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as drug targets. It has five drug programs in various stages of clinical development and has advanced small molecule compounds from a number of additional drug programs into various stages of preclinical development and research. Its drug program includes LX4211,
Will LXRX Continue To Move Higher? Find Out Here
Coronado Biosciences Inc (NASDAQ:CNDO) opened the session at $2.10 and closed the session at $2.21. The stock showed a positive performance of 5.74% in previous trading session. Traded with volume of 1.05 million shares in the prior session and the average volume of the stock remained 2.11 million shares. Coronado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. The Company’s two principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201 (TSO) a biologic comprising of the microscopic eggs of the porcine whipworm, for the treatment of autoimmune diseases, such as Crohn’s disease (Crohn’s), ulcerative colitis (UC) and multiple sclerosis (MS), and CNDO-109,
For How Long CNDO will fight for Profitability? Read This Trend Analysis report
Cereplast Inc (OTCMKTS:CERP) opened the session at $0.01 and closed the session at 0.0055. The stock showed a positive performance of 7.84% in previous trading session. Traded with volume of 9.74 million shares in the prior session and the average volume of the stock remained 5.22 million shares. The beta of the stock remained 0.57. Cereplast, Inc. (Cereplast) is engaged in developing and commercializing bio-based resins through two product families: Cereplast Compostables Resins, which are compostable, renewable, ecologically sound substitutes for petroleum-based plastics, and Cereplast Sustainables resins (including the Cereplast Hybrid Resins product line), which replaces up to 90% of the petroleum-based content of traditional plastics with materials from renewable resources. The Company primarily conducts its operations through product families,
Why Should Investors Buy CERP After The Recent Gain? Just Go Here and Find Out
Dendreon Corporation (NASDAQ:DNDN) the stock advanced 0.30% and finished the session at $3.33. Traded with volume of 5.69 million shares in the prior session and the average volume of the stock remained 3.83 million shares. The beta of the stock remained 5.04. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients. The Company's product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers. PROVENGE (sipuleucel-T), is the Company's first commercialized product approved by the United States Food and Drug Administration (FDA), and is a autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic,
Will DNDN Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)